Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Covered in this story
Call it yourself
No calls on $CMPX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Compass Therapeutics →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.